Health ❯ Healthcare ❯ Pharmaceuticals

Biosimilars

Regulatory Approvals Drug Approval Cancer Treatment Market Opportunities Nufymco Regulatory Guidance Synthetic Drugs Insulin Keytruda Biosimilar Drugs

FDA Approves Langlara as Interchangeable Biosimilar to Lantus

Pharmacy-level substitution could expand access.

Health Canada Clears Biocon’s Denosumab Biosimilars Bosaya and Vevzuo

FDA Clears Teva’s Ponlimsi, a Prolia Biosimilar, for All Indications

Semaglutide Patent Expires in Brazil, Opening Door to Lower-Cost Rivals

Zydus Launches Low-Cost Nivolumab Biosimilar Tishtha in India After Court Greenlight

Delhi High Court Allows Zydus to Market Nivolumab Biosimilar on Public‑Interest Grounds

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

US FDA Clears Lupin’s Armlupeg, a Neulasta Biosimilar, for U.S. Use

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer

Sun Pharma Logs Modest Q2 Growth as U.S. Innovator Drugs Overtake Generics; Lupin Profit Jumps on Strong U.S. Demand

FDA Proposes Faster Biosimilar Approvals by Dropping Routine Human Trials

NHS England Faces Concerns Over MS Drug Switch After Reports of Severe Side Effects